UK advances sweeping veterinary reforms on pricing and oversight

The UK veterinary sector is heading into its biggest structural shake-up in decades, with two related but distinct reform tracks now in motion. On March 24, 2026, the Competition and Markets Authority concluded its veterinary services market investigation and ordered a package of legally binding remedies aimed at making pricing, ownership, and treatment choices clearer for pet parents. Separately, the UK government has been consulting on a broader rewrite of the Veterinary Surgeons Act 1966, a move that could bring mandatory regulation or licensing of veterinary businesses and expand the formal regulatory framework around the wider veterinary team. (gov.uk)

The backdrop is a long-running concern that the UK companion animal market has changed faster than its rules. The CMA launched its review in September 2023 and later escalated to a full market investigation, drawing roughly 56,000 responses from the public and the profession. The regulator said pet parents often lacked basic information about prices, medicines, ownership structures, and treatment options, while the market became increasingly concentrated among six large veterinary groups: CVS, IVC, Linnaeus, Medivet, Pets at Home, and VetPartners. The UK government, meanwhile, said the underlying legislation has remained largely unchanged since 1966 and no longer reflects how modern veterinary practice operates. (gov.uk)

The CMA’s final remedies are more specific than the earlier political headlines about “reform.” According to the regulator, practices will have to provide clearer pricing information, while written prescription fees will be capped at £21 for the first medicine and £12.50 for additional medicines. Corporate groups will have to make ownership more visible, pet care plans will need to show component pricing and explain any claimed savings, and practices will have to provide clearer cremation pricing, including lower-cost communal options where relevant. The CMA also said price and ownership data will feed into the Royal College of Veterinary Surgeons’ Find a Vet service and third-party comparison tools, and that out-of-hours providers will be barred from using unreasonably long notice periods that make switching difficult. The CMA has until September 23, 2026, to put orders and undertakings in place, with most remedies then phased in over the following three to 12 months. (gov.uk)

Alongside that, Defra’s January 27, 2026 reform package framed the issue more broadly than pricing alone. The government said problems identified by the CMA could cost households up to £1 billion over five years, and it cited findings that vet fees had risen at nearly twice the rate of inflation. Its consultation on the Veterinary Surgeons Act proposed official operating licenses for practices, stronger complaints processes, regulation of veterinary businesses rather than only individual professionals, legal recognition for veterinary nurses, and a more modern governance model for the RCVS. The consultation opened on January 28 and closed on March 25, 2026, making the next government response an important milestone. (gov.uk)

Professional reaction has been broadly supportive of the direction of travel, especially on transparency and long-delayed legislative modernization, but not without caution. A joint response from BVA, BSAVA, BVNA, SPVS, and VMG supported standard price publication as a way to improve transparency and competition, while raising concerns that some medicines-related remedies could distort prescribing or push business toward online pharmacies, including pharmacies linked to larger groups. The RCVS has also argued for a new Veterinary Surgeons Act for years and publicly backed reform of the outdated statute, while emphasizing the need to avoid unintended consequences in areas such as medicines and governance. Industry coverage after the final CMA decision similarly reported broad support paired with concern about compliance burden and cost, particularly for smaller practices. (bsava.com)

Why it matters: For veterinary professionals, the UK story is important not just because it targets costs, but because it links consumer protection, competition policy, and professional regulation in one package. If business licensing or mandatory regulation moves forward, accountability in the UK would shift more directly onto practice entities, not only individual veterinarians and nurses. Operationally, practices may need new pricing architecture, website updates, estimate templates, medicine-dispensing protocols, complaints handling systems, and clearer internal safeguards around clinical independence. For independent hospitals and smaller groups, the burden may be manageable but still material, especially where margins are already tight and medicine revenue helps subsidize care delivery. (gov.uk)

For U.S. readers, the UK reforms also offer a live policy test of issues that are increasingly familiar elsewhere: private equity and corporate consolidation, transparency in bundled wellness plans, prescription portability, and the question of whether business entities should face direct regulatory oversight. The UK is further along than many markets in translating those concerns into formal remedies. Whether the changes actually lower costs, improve trust, or simply redistribute administrative burden will be closely watched by veterinary leaders well beyond Britain. That last point is an inference, but it follows from the breadth of the CMA package and the government’s parallel effort to modernize the profession’s legal framework. (gov.uk)

What to watch: The immediate next step is the CMA’s final implementation orders, due by September 23, 2026, followed by staggered compliance deadlines into late 2026 and 2027; after that, attention will turn to how the UK government responds to the Veterinary Surgeons Act consultation and whether mandatory business licensing and broader statutory reform advance into legislation. (gov.uk)